Mycenax Biotech (ROCO:4726) Cyclically Adjusted Revenue per Share: NT$4.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4726 Mycenax Biotech Inc ROCO:4726
47 GF Score
Price NT$24.20
GF Value NT$46.61
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Mycenax Biotech Cyclically Adjusted Revenue per Share?

Mycenax Biotech ROCO:4726 47 Cyclically Adjusted Revenue per Share is NT$4.35 as of Jun. 2026. GuruFocus rates ROCO:4726 with a GF Score™ of 47/100 and a GF Value™ of NT$46.61 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mycenax Biotech's adjusted revenue per share for the three months ended in Jun. 2026 was NT$0.984. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$4.35 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Mycenax Biotech's average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Mycenax Biotech was 17.80% per year. The lowest was 9.10% per year. And the median was 13.30% per year.

As of today (2026-08-31), Mycenax Biotech's current stock price is NT$24.20. Mycenax Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was NT$4.35. Mycenax Biotech's Cyclically Adjusted PS Ratio of today is 5.56.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mycenax Biotech was 20.81. The lowest was 5.56. And the median was 11.98.


Mycenax Biotech  (ROCO:4726) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mycenax Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=24.20/4.35
=5.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mycenax Biotech was 20.81. The lowest was 5.56. And the median was 11.98.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mycenax Biotech Cyclically Adjusted Revenue per Share Related Terms


Mycenax Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Mycenax Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mycenax Biotech Cyclically Adjusted Revenue per Share Chart

Mycenax Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.61 3.15 3.50 3.80 4.09

Mycenax Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 4.03 4.09 4.25 4.35

ROCO:4726 vs VRTX, REGN, MRNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Mycenax Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mycenax Biotech Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mycenax Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mycenax Biotech's Cyclically Adjusted PS Ratio falls into.


ROCO:4726
47GF Score
Mycenax Biotech Inc ROCO:4726
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mycenax Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mycenax Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.984/333.9520*333.9520
=0.984

Current CPI (Jun. 2026) = 333.9520.

Mycenax Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.785 241.428 1.086
201612 0.655 241.432 0.906
201703 0.230 243.801 0.315
201706 0.679 244.955 0.926
201709 1.143 246.819 1.547
201712 0.846 246.524 1.146
201803 0.159 249.554 0.213
201806 0.445 251.989 0.590
201809 0.541 252.439 0.716
201812 0.786 251.233 1.045
201903 0.558 254.202 0.733
201906 0.911 256.143 1.188
201909 0.612 256.759 0.796
201912 1.027 256.974 1.335
202003 0.546 258.115 0.706
202006 2.120 257.797 2.746
202009 1.190 260.280 1.527
202012 1.387 260.474 1.778
202103 2.173 264.877 2.740
202106 0.695 271.696 0.854
202109 1.013 274.310 1.233
202112 1.440 278.802 1.725
202203 1.462 287.504 1.698
202206 0.990 296.311 1.116
202209 1.031 296.808 1.160
202212 0.984 296.797 1.107
202303 0.674 301.836 0.746
202306 1.068 305.109 1.169
202309 0.548 307.789 0.595
202312 0.889 306.746 0.968
202403 0.390 312.332 0.417
202406 0.967 314.175 1.028
202409 1.013 315.301 1.073
202412 0.940 315.605 0.995
202503 0.584 319.799 0.610
202506 0.975 322.561 1.009
202509 0.637 324.800 0.655
202512 1.373 324.054 1.415
202603 0.942 330.213 0.953
202606 0.984 333.952 0.984

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$4.35 mean?
Mycenax Biotech (ROCO:4726) has a Cyclically Adjusted Revenue per Share of NT$4.35 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mycenax Biotech and its competitors.
Is Mycenax Biotech's Cyclically Adjusted Revenue per Share too high?
Mycenax Biotech's current Cyclically Adjusted Revenue per Share is NT$4.35. Overall, Mycenax Biotech has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Mycenax Biotech's Cyclically Adjusted Revenue per Share of NT$4.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mycenax Biotech and its competitors. Mycenax Biotech's current Cyclically Adjusted Revenue per Share is NT$4.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$46.61, compared to a current price of NT$24.20 — trading 48.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$4.35. Mycenax Biotech's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current Cyclically Adjusted Revenue per Share is NT$4.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?

Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued. The current stock price of NT$24.20 is trading 48.1% below its estimated GF Value™ of NT$46.61. GuruFocus considers Mycenax Biotech to be Possible Value Trap.

Key valuation signals for ROCO:4726:

  • Cyclically Adjusted Revenue per Share: NT$4.35
  • GF Value™: NT$46.61 vs. price of NT$24.20 (48.1% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mycenax Biotech Business Description

Address No. 66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
47GF Score

Get the complete analysis for ROCO:4726

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.20
Price
NT$46.61
GF Value